Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Authors :: Yeung, Kay T
Kalinsky, Kevin
Yau, Christina
Chien, Amy Jo
Boughey, Judy Caroline
Stringer-Reasor, Erica Michelle
Falkson, Carla Isadora
Albain, Kathy S.
Mayer, Ingrid A.
Trivedi, Meghna S.
Nanda, Rita
Douglas, Emily H.
Omene, Coral Oghenerukevwe
Rugo, Hope S.
Isaacs, Claudine
Parker, Beverly
DeMichele, Angela
Yee, Douglas
Esserman, Laura
Source :: Journal of Clinical Oncology; 6/10/2023 Supplement17, Vol. 41, pLBA520-LBA520, 1p
Publication Year :: 2023

Full Text Access

Tools